Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.04 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: dantrolene, dantrolene sodium | 1.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 5 Parkinson's papers of 2,228 | 0.76 |
| pathways Reactome | 2 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 5995
Sealed predictions
- RYR1 in dopamine neurons, braak-0.15 (p 0.705) → -0.75 (p 0.019)receipt 6001
Swarm cases
receipt 6001: RYR1 in dopamine neurons, braak
- power
- full sample -0.41 (p 0.095, n 18), 95% CI -0.73 to +0.08. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.43 (p 0.079, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.54 (p 0.020, n 18). not the mix.
- skeptic
- leave-one-out range -0.49 to -0.33, sign flips 0; without severely affected donors -0.41 (p 0.095, n 18). robust.
- cell type
- strongest in microglia: -0.63 (p 0.0047, n 18) vs -0.41 in dopamine neurons. proposing microglia.
- axis
- no measure beats "tracks Braak Lewy-body stage" for RYR1 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up RYR1 · microglia · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) -0.50 p 0.076 (needs p < 3.3e-4)
Receipts
loading the receipts